CD5 and diffuse large B-cell lymphoma: The 5‐year EFS rates for patients with CD5+ vs CD5− DLBCL were 11.7% vs 52.1%, and the 5‐year OS rates for patients with CD5+ vs CD5− DLBCL were 19.4% vs 56.2%, respectively.